权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Enhancing Photodynamic Therapy for Treating Kaposi's Sarcoma

加强光动力疗法治疗卡波西肉瘤

基本信息

批准号：
7268113
负责人：
CHARLES Joseph GOMER
金额：
$ 14.05万
依托单位：
CHILDREN'S HOSPITAL OF LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-08-01 至 2008-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7268113
关键词：
AIDS with Kaposi&apos s sarcoma Acquired Immunodeficiency Syndrome Address Affect Aftercare Angiogenesis Inhibitors Apoptosis Avastin Carcinoma Clinical Clinical Treatment Clinical Trials DC101 Monoclonal Antibody Data Development Effectiveness Exhibits Funding Goals Highly Active Antiretroviral Therapy Human Immune Immunosuppressive Agents Individual Kaposi Sarcoma Lesion Malignant Neoplasms Measurement Mediating Medical Modality Modeling Mus NIH Program Announcements Neoplasm Transplantation Normal tissue morphology Nude Mice Outcome Patients Pharmaceutical Preparations Phosphorylation Photochemotherapy Photosensitization Phototoxicity Procedures Protein Overexpression Quality of life Radiation therapy Receptor Protein-Tyrosine Kinases Recurrence Reporting Request for Applications Research Research Personnel Signal Transduction Skin Skin Neoplasms Therapeutic Therapeutic procedure Toxic effect Treatment Efficacy Treatment Protocols United States National Institutes of Health Vascular Endothelial Growth Factor Receptor-2 Vascular Endothelial Growth Factors Xenograft Model ZD-6474 angiogenesis chemotherapy density design improved in vivo inhibitor/antagonist innovation novel novel therapeutics pre-clinical programs psychologic research study response therapeutic effectiveness tumor tumor xenograft

项目摘要

DESCRIPTION (provided by applicant): Kaposi's sarcoma (KS) continues to be a major medical challenge in HIV-AIDS patients even with the extensive use of highly active antiretroviral therapy. This malignancy can have both psychological and physically debilitating affects that negatively impact quality of life. A variety of treatment approaches are being used but unfortunately effective long term palliation of KS remains difficult to achieve. Photodynamic therapy (PDT) has been used in the treatment of KS and has been reported to be effective in part because the procedure can be repeated and is not associated with either immunosuppressive activity or significant systemic toxicity. However, results from previous PDT clinical trials for KS demonstrated that the procedure has not been optimized and recurrences can occur. We propose a novel exploratory project designed specifically to enhance the local tumoricidal response of PDT using angiogenic inhibitors. This application builds upon our recent discovery that PDT induces overexpression of vascular endothelial growth factor (VEGF) and that angiogenic inhibitors can improve PDT responsiveness in murine carcinomas. We also have new preliminary data documenting that PDT also increases VEGF levels in a human KS xenograft model. We hypothesize that PDT induced expression of VEGF decreases treatment efficacy and that a combined modality approach employing PDT and angiogenic inhibitors will be effective in treating KS without inducing a concomitant increase in normal tissue toxicity. The goal of our R21 application is to determine whether drugs selectively inhibiting various components of VEGF signaling will improve the treatment of human KS tumors using PDT. This will be accomplished through in-vivo analysis of treatment responsiveness of human KS tumors transplanted in nude mice. Anti-angiogenic agents that target VEGF (Avastin), VEGF receptor-2 (DC101), or the receptor tyrosine kinase [ZD6474] will be evaluated in experiments designed to examine tumor and normal tissue response. The overall objective of this research is to obtain translational data justifying a novel clinical approach to improve the efficacy of PDT for treating KS. The successful completion of this objective would result in an improved treatment option for KS that exhibits minimal toxicity and which can be used repeatedly and following chemotherapy and/or radiation therapy.

描述（由申请人提供）：卡波西肉瘤（KS）仍然是一个主要的医疗挑战，在艾滋病毒/艾滋病患者，即使广泛使用的高活性抗逆转录病毒治疗。这种恶性肿瘤可以有心理和身体衰弱的影响，负面影响生活质量。各种治疗方法正在使用，但不幸的是，有效的长期缓解KS仍然难以实现。光动力疗法（PDT）已被用于治疗KS，并已被报道是有效的，部分原因是该程序可以重复，并且与免疫抑制活性或显著的全身毒性无关。然而，先前PDT治疗KS的临床试验结果表明，该手术尚未优化，可能会发生复发。我们提出了一个新的探索性项目，专门设计，以提高局部肿瘤杀伤反应的PDT血管生成抑制剂。本申请建立在我们最近的发现，PDT诱导血管内皮生长因子（VEGF）的过度表达和血管生成抑制剂可以提高PDT在小鼠肿瘤的反应。我们也有新的初步数据证明PDT也增加了人KS异种移植模型中的VEGF水平。我们假设PDT诱导的VEGF表达会降低治疗效果，并且采用PDT和血管生成抑制剂的联合治疗方法将有效治疗KS，而不会导致正常组织毒性的同时增加。我们的R21申请的目标是确定选择性抑制VEGF信号传导的各种组分的药物是否会改善使用PDT的人KS肿瘤的治疗。这将通过在裸鼠中移植的人KS肿瘤的治疗反应性的体内分析来实现。将在旨在检查肿瘤和正常组织反应的实验中评价靶向VEGF（安维汀）、VEGF受体-2（DC 101）或受体酪氨酸激酶[ZD 6474]的抗血管生成药物。本研究的总体目标是获得翻译数据，证明一种新的临床方法，以提高PDT治疗KS的疗效。该目标的成功完成将导致KS的改善的治疗选择，其表现出最小的毒性，并且可以在化疗和/或放疗后重复使用。